Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on In-vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis

NCT00633022 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00633022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00633022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on In-vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
June 2, 2008
Completion date
December 3, 2009
Enrollment
99 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis